On September 27, 2023, the U.S. Food and Drug Administration (FDA) put into motion its definitive guidelines on the matter of premarket cybersecurity for medical devices. Officially titled “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions”, this Final Guidance replaces the direction provided in 2014 and the subsequent draft guidance that was published in April 2022.
The 2023 Final Guidance indicates significant changes to the FDA’s stance when juxtaposed to the 2014 Guidance. The three primary modifications center around the agency’s interpretation of the Quality System Regulations (QSR), the shift in focus on design controls to adequately address cybersecurity risks and vulnerabilities, and the inclusion of cybersecurity in the Risk Analysis required under 21 CFR 820.30(g).
The FDA’s finalized guidance encourages the active implementation of methods thats neutralize potential cybersecurity threats in medical devices from the earliest phase, starting right from the design controls. This approach is an essential derivative of the agency’s perspective that stresses on addressing these cybersecurity risks during the development stage itself, rather than including fixes in the post-market phase. The emphasis is on preemptive actions and the ‘security by design’ concept.
The agency also focuses on the inclusion of cybersecurity within 21 CFR 820.30(g)’s Risk Analysis. This is a vital shift from prior guidance which treated cybersecurity predominantly within post-market surveillance and correction. Now, it’s fully integrated within premarket submissions.
This Final Guidance signifies the growing importance of cybersecurity in medical devices, a trend mirrored internationally. For manufacturers and legal professionals, this presents dual challenges of familiarising themselves with these new changes and ensuring that procedures and documentation align with the newly established guidelines. A failure to meet these new guidelines can result in regulatory actions and delayed clearances for market entrance for their products. Fully understanding this guidance and aligning operations with its dictates is a crucial step forward for any legal professional involved with medical devices.
The 2023 Final Guidance can be seen as a crucial advancement in securing medical devices against potential cyber threats. With an increasingly digital medical industry, these measures ensure the safety and reliability of these life-saving appliances and thereby, indirectly, of the patients dependent on them.